By Nana O 
Researchers at the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have unveiled groundbreaking findings that redefine the understanding of glioblastoma, the most aggressive and lethal form of brain cancer. Their study, published on October 3 in the prestigious journal Nature Neuroscience, reveals that glioblastoma does not merely invade and destroy brain tissue. Instead, it engages in a complex, multi-faceted attack that extends to the skull itself, significantly altering the bone marrow within, and profoundly disrupting the body’s intricate immune system. This paradigm-shifting discovery suggests that existing therapeutic strategies, which predominantly view glioblastoma as a localized disease, may be fundamentally flawed and necessitates a re-evaluation of treatment approaches.
The research team’s investigation, led by Dr. Jinan Behnan, an assistant professor in the Leo M. Davidoff Department of Neurological Surgery and the department of Microbiology & Immunology at Einstein and a member of the NCI-designated MECCC, indicates that certain medications designed to combat bone loss could inadvertently accelerate glioblastoma’s progression, highlighting a critical and previously unrecognized vulnerability in treatment.
A Systemic Assault: Beyond Brain Tissue
Glioblastoma, a notoriously difficult cancer to treat, affects an estimated 15,000 individuals annually in the United States. Despite current standard-of-care protocols, which typically involve a combination of surgery, chemotherapy, and radiation, the median survival time for patients remains tragically short, hovering around 15 months. This stark reality has fueled the urgent search for novel therapeutic targets and a deeper comprehension of the tumor’s biological behavior.
"Our discovery that this notoriously hard-to-treat brain cancer interacts with the body’s immune system may help explain why current therapies — all of them dealing with glioblastoma as a local disease — have failed, and it will hopefully lead to better treatment strategies," stated Dr. Behnan, the paper’s corresponding author. This sentiment underscores the profound implications of the findings, suggesting that a systemic approach, rather than a localized one, is crucial for effective glioblastoma management.
The Crucial Role of Skull Marrow
The skull, often perceived as a mere protective casing for the brain, harbors bone marrow that plays a vital role in the production of immune cells and other essential blood components. Dr. Behnan’s team was motivated by recent scientific revelations demonstrating the existence of incredibly fine channels connecting the skull to the brain. These micro-channels facilitate the critical exchange of molecules and immune cells between these two distinct yet interconnected environments.
Utilizing sophisticated imaging technologies, the researchers meticulously examined mice that had developed two distinct types of glioblastoma. Their observations revealed a disturbing pattern: the cancer actively induced erosion of the skull bones, with the most pronounced damage occurring along the sutures, the fibrous joints where skull bones fuse. This specific type of bone degradation was found to be uniquely associated with glioblastoma and other aggressive brain tumors. Crucially, this phenomenon was not observed in mice experiencing strokes, other forms of brain injury, or cancers located elsewhere in the body, reinforcing the notion of glioblastoma’s specific tropism for cranial bone. Further validation of these findings in human patients came from CT scans, which showed similar reductions in skull thickness in regions corresponding to those affected in the mouse models.
The study’s findings suggest that the erosion of skull bone leads to an increase in both the number and diameter of the channels linking the skull and brain. The researchers theorize that these enlarged conduits act as pathways for the tumor to transmit molecular signals into the skull marrow, thereby manipulating and altering its immune microenvironment. This creates a feedback loop where the cancer actively reshapes its surroundings to its own advantage.
Shifting the Immune Landscape: A Pro-Inflammatory Tilt
Through the application of advanced single-cell RNA sequencing techniques, the research team identified a dramatic shift in the immune-cell composition of the skull marrow. Glioblastoma was found to have profoundly favored the proliferation of pro-inflammatory myeloid cells, leading to a near doubling of inflammatory neutrophils. Concurrently, the cancer significantly diminished the presence of several types of antibody-producing B cells, as well as other B cell populations. This drastic alteration in the immune cell balance creates an environment conducive to tumor growth and survival.
"The skull-to-brain channels allow an influx of these numerous pro-inflammatory cells from the skull marrow to the tumor, rendering the glioblastoma increasingly aggressive and, all too often, untreatable," explained Dr. E. Richard Stanley, a professor of Developmental and Molecular Biology at Einstein and a co-author of the study. This statement emphasizes the direct causal link between the altered skull marrow environment and glioblastoma’s recalcitrant nature.
Dr. Stanley further elaborated on the therapeutic implications: "This indicates the need for treatments that restore the normal balance of immune cells in the skull marrow of people with glioblastoma. One strategy would be suppressing the production of pro-inflammatory neutrophils and monocytes while at the same time restoring the production of T and B cells." Such a targeted approach, aimed at re-establishing immune homeostasis within the skull marrow, could represent a significant breakthrough in glioblastoma therapy.
Adding another layer to the complexity of glioblastoma’s systemic impact, the study revealed differential responses between the skull marrow and the femur marrow. While glioblastoma activated genes in the skull marrow that promoted the production of inflammatory immune cells, the cancer had the opposite effect on the femur marrow, suppressing genes essential for the production of various immune cell types. This stark contrast underscores that glioblastoma is not a uniform disease and its systemic effects are nuanced and region-specific, further challenging the notion of it being purely a local affliction.
The Paradox of Osteoporosis Medications
Intrigued by the observed bone erosion, the researchers hypothesized that medications designed to prevent bone loss, such as those used to treat osteoporosis, might influence glioblastoma progression. To test this, they administered two FDA-approved osteoporosis drugs, zoledronic acid and denosumab, to mice bearing glioblastoma tumors.
The results were complex and revealed a paradoxical effect. Both drugs successfully halted the erosion of skull bones. However, zoledronic acid, in one type of glioblastoma model, unexpectedly accelerated tumor progression. Furthermore, both osteoporosis medications interfered with the efficacy of anti-PD-L1, an immunotherapy drug known to enhance the activity of tumor-fighting T cells. This finding is particularly concerning, as it suggests that common treatments for osteoporosis could potentially compromise the effectiveness of existing cancer immunotherapies, a critical consideration for patients with co-existing conditions.
Timeline of Discovery and Future Directions
The genesis of this research can be traced back to a growing body of evidence suggesting that the brain microenvironment plays a more active role in cancer progression than previously understood. The identification of skull-brain channels provided a crucial anatomical link for investigation.
Early Stages (Hypothesis Formulation): Inspired by recent anatomical discoveries of skull-brain channels, researchers began to hypothesize a potential interplay between the skull and brain, particularly in the context of aggressive brain tumors.
Pre-clinical Investigation (Mouse Models): The research team initiated experiments using mouse models of glioblastoma. Advanced imaging techniques were employed to observe the direct effects of the tumor on skull bone integrity.
Key Observation (Bone Erosion): Researchers noted significant erosion of skull bones in mice with glioblastoma, particularly around the cranial sutures. This effect was specific to aggressive brain tumors.
Molecular and Cellular Analysis (Immune Shift): Single-cell RNA sequencing was utilized to analyze the immune cell composition of the skull marrow. This revealed a dramatic shift towards pro-inflammatory myeloid cells and a depletion of certain B cell populations.
Human Correlation: CT scans of human glioblastoma patients were analyzed to corroborate the findings observed in mice, showing similar skull bone thinning.
Therapeutic Intervention Testing: Osteoporosis medications were administered to glioblastoma-bearing mice to assess their impact on bone erosion and tumor progression.
Publication of Findings: The comprehensive results were published in Nature Neuroscience on October 3, 2023, marking a significant milestone in glioblastoma research.
The implications of these findings are far-reaching. They strongly suggest that glioblastoma should be viewed as a systemic disease with significant impact beyond the brain parenchyma. This necessitates a paradigm shift in treatment strategies, moving away from solely localized interventions to approaches that address the tumor’s interaction with the skull and the broader immune system. Future research will likely focus on developing therapies that can restore the normal immune balance within the skull marrow, potentially by modulating neutrophil and monocyte production while simultaneously boosting T and B cell populations. Furthermore, understanding the interplay between glioblastoma and bone health, particularly in the context of osteoporosis treatments, will be crucial for optimizing patient care.
The collaborative nature of this research, involving institutions across the globe including Osaka University in Japan, Karolinska Hospital in Sweden, Duke University Medical Center in North Carolina, the University of California, San Francisco, and the German Rheumatism Research Center, highlights the international effort to combat this devastating disease. The comprehensive list of authors, including Abhishek Dubey, Biljana Stangeland, Imane Abbas, David Fooksman, Ph.D., Wade R. Koba, B.S., Jinghang Zhang, M.D., Benjamin T. Himes, Ph.D., Derek Huffman, Ph.D., Zhiping Wu, Rachel Welch, David Reynolds, B.S., Kostantin Dobrenis, Ph.D., Qinge Ye, Kevin Fisher, and Emad Eskandar, M.D. from MECCC and Einstein, along with international collaborators Erika Yamashita, Yutaka Uchida and Masaru Ishii, Robert A. Harris, Gregory M Palmer, Olivia R. Lu and Winson S. Ho, and Alexander F. Fiedler, underscores the significant scientific endeavor behind this groundbreaking publication.
This research not only illuminates the intricate mechanisms by which glioblastoma operates but also opens new avenues for therapeutic intervention, offering a glimmer of hope for patients facing this formidable diagnosis. The journey from understanding the fundamental biology of the disease to developing effective treatments is often long and arduous, but discoveries like these represent critical steps forward.